Cannabinoid Vaping Products: Regulation, Composition, Toxicological Effects, and Emerging Research

Area of Science:

• Pulmonology
• Toxicology
• Regulatory Science

Background:

• The 2018 Farm Bill legalized hemp-derived cannabinoids, leading to an unregulated market of vaping products.
• These products, containing high cannabinoid concentrations (e.g., cannabidiol, Δ8-tetrahydrocannabinol) and contaminants, raise significant respiratory toxicity concerns.

Purpose of the Study:

• To review the regulatory status, manufacturing, composition, and toxicological mechanisms of hemp-derived cannabinoid vaping products.
• To identify research gaps and inform public health and regulatory strategies for safer products.

Main Methods:

• Comprehensive literature review of existing studies on cannabinoid vaping products.
• Analysis of regulatory frameworks, manufacturing practices, product composition, and toxicological data.
• Examination of potential injury mechanisms, including inflammatory responses, oxidative stress, and the role of specific byproducts.

Main Results:

• Vaping-related lung injuries, like EVALI, have been reported, though mechanisms remain unclear.
• Multiple toxicity pathways identified, including inflammation, oxidative stress from contaminants, and novel reactive cannabinoid quinones (e.g., CBDQ).
• Cannabinoid quinones may alter protein function and drive oxidative damage, contributing significantly to toxicity.

Conclusions:

• Understanding the complex toxicological mechanisms of cannabinoid vaping is crucial for public health.
• Further research is essential on chronic exposure, injury mechanisms, and the interplay of various harmful components.
• Optimizing vaping temperatures and formulations is necessary to balance potential therapeutic benefits with safety concerns.